ZELTIQ to Present at Canaccord Genuity Medical Technology and Diagnostics Forum
October 31 2013 - 4:05PM
ZELTIQ® (Nasdaq:ZLTQ), a medical technology company focused on
developing and commercializing products utilizing its proprietary
controlled-cooling technology platform, today announced that Mark
Foley, President and Chief Executive Officer and Patrick F.
Williams, Senior Vice President and Chief Financial Officer, are
scheduled to present at the Canaccord Genuity Medical Technology
and Diagnostics Forum at The Westin Grand Central in New York City.
Event: Canaccord Genuity Medical Technology and
Diagnostics Forum Date: November 14, 2013
Time: 10:00 a.m. ET
An audio webcast of the Company's presentation will be available
by visiting the investor relations section of ZELTIQ's web site at
www.coolsculpting.com. A replay of the presentation will be
available for 90 days.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ is a medical technology company focused on developing and
commercializing products utilizing its proprietary
controlled-cooling technology platform. ZELTIQ's first commercial
product, the CoolSculpting System, is designed to selectively
reduce stubborn fat that may not respond to diet or exercise.
CoolSculpting is based on the scientific principle that fat cells
are more sensitive to cold than the overlying skin and surrounding
tissues. It utilizes patented technology of precisely
controlled cooling to reduce the temperature of fat cells in the
treated area, which is intended to cause fat cell elimination
through a natural biological process known as
apoptosis. ZELTIQ developed CoolSculpting to safely,
noticeably, and measurably reduce the fat layer.
CONTACT: Investor Relations:
Patrick F. Williams
ZELTIQ, Senior Vice President and CFO
925-474-2500
Nick Laudico / Rada Milenovici
The Ruth Group
646-536-7030 / 646-536-7011
nlaudico@theruthgroup.com
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jul 2023 to Jul 2024